Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates.
- 1 January 1997
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 35 (2) , 101-112
- https://doi.org/10.1023/a:1005822524905
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- A pilot study of monoclonal antibody targeted radiotherapy in the treatment of central nervous system leukaemia in childrenBritish Journal of Haematology, 2008
- Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8Journal of Neuro-Oncology, 1993
- Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetryBritish Journal of Cancer, 1993
- 1-(meta-[211At]Astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluationBioconjugate Chemistry, 1992
- A novel O‐acetylated ganglioside detected by anti‐GD2 monoclonal antibodiesInternational Journal of Cancer, 1992
- Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomasActa Neuropathologica, 1991
- Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitisBritish Journal of Cancer, 1990
- Complete Tumor Ablation With Iodine 131-Radiolabeled Disialoganglioside GD2-Specific Monoclonal Antibody Against Human Neuroblastoma Xenografted in Nude Mice23JNCI Journal of the National Cancer Institute, 1986
- Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.1985
- Gangliosides of Human Cerebral AstrocytomasJournal of Neurochemistry, 1980